The Latest Breaking News from AstraZeneca

Claire Spragg was diagnosed with triple negative breast cancer and discovered she carried the faulty BRCA2 gene. She was able to take a year's supply of olaparib, which is now available on the NHS

Lisa Shaw, 44, who worked for BBC Radio Newcastle, died a week after her first jab

Clinical trials have shown the drug could extend advanced prostate cancer patients’ lives by an average of six months, NHS England said

AstraZeneca said Wednesday a combination of its drugs Lynparza and Imfinzi met the goal of a key study, leading AZN stock to surge.

On May 11, 2020 a deadly threat flew from Los Angeles to New York City in under nine minutes. It was a 20-tonne Chinese Long March 5B rocket body passing around 60 miles overhead.

Measure over next three years will allow firms to write off costs of IT equipment and machinery against tax on profits

Under the Vaccine Damage Payment Scheme, those harmed by the coronavirus jab get a £120,000 payment but thousands are still waiting for their claims to be assessed

Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies.

Strong fundamentals and bright prospects of AstraZeneca (AZN), trading below $100 a share, could help investors secure decent risk-adjusted returns on their investments in a choppy market environment. Read on….

AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are…

Leaders of Tory several factions write to PM urging rethink